Want to see TSE:MRVL full AI Analyst Report?
Marvel Biosciences Corp (MRVL) Ratios
Marvel Biosciences Corp Ratios
TSE:MRVL's free cash flow for Q3 2026 was $164.13K. For the 2026 fiscal year, TSE:MRVL's free cash flow was increased by $4.00 and operating cash flow was $164.13K. See a summary of the company’s cash flow.
| Ratios | Oct 25 | Oct 24 | Oct 23 | Oct 22 | Jul 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.08 | 0.31 | 0.48 | 1.27 | 21.94 |
| Quick Ratio | 0.08 | 0.31 | 0.48 | 1.27 | 21.94 |
| Cash Ratio | 0.03 | 0.22 | 0.40 | 0.83 | 21.28 |
| Solvency Ratio | -0.51 | -0.00 | -0.93 | -3.56 | -27.02 |
| Operating Cash Flow Ratio | -0.27 | -0.73 | -0.96 | -3.06 | -12.19 |
| Short-Term Operating Cash Flow Coverage | -0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -4.01M | $ -2.83M | $ -1.72M | $ 195.54K | $ 2.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 7.07 | 3.48 | 1.49 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.58 | -0.61 | -0.58 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -1.36 | -1.53 | -1.39 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -1.53 | -1.39 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.08 | -0.17 | -0.39 | 4.67 | 1.05 |
| Debt Service Coverage Ratio | -0.75 | -13.48 | -65.10 | -1651.58 | -1603.16 |
| Interest Coverage Ratio | -4.66 | -0.01 | -67.04 | -1642.33 | 409.72 |
| Debt to Market Cap | 0.28 | 0.36 | 0.32 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.05 | 0.03 | 0.00 | 0.00 |
| Net Debt to EBITDA | -1.12 | -0.89 | -0.20 | 0.23 | 1.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 177.10% | 134.80% | 98.81% | 100.40% | -376.93% |
| Return on Assets (ROA) | -676.88% | -0.34% | -340.78% | -279.59% | -123.14% |
| Return on Equity (ROE) | 55.20% | 0.06% | 133.21% | -1306.22% | -129.02% |
| Return on Capital Employed (ROCE) | 31.17% | 0.11% | 322.03% | -1301.02% | 34.23% |
| Return on Invested Capital (ROIC) | 73.61% | 0.11% | 322.03% | -1301.02% | 34.23% |
| Return on Tangible Assets | -676.88% | -0.34% | -340.78% | -279.59% | -123.14% |
| Earnings Yield | -26.71% | -0.03% | -72.22% | -91.73% | -38.86% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.36 | 0.00 | 0.73 | 5.25 | 392.26 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1000.45 | 0.00 | -496.98 | -69.47 | -0.93 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1000.45 | 0.00 | 496.98 | 69.47 | 0.93 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.03 | -0.03 | -0.07 | -0.04 |
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.03 | -0.07 | -0.04 |
| Dividend Paid and CapEx Coverage Ratio | -383441.00 | 0.00 | -266447.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -383441.00 | 0.00 | -266447.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.50 | -0.69 | -1.33 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.90% | -24.60% | -41.99% | -78.79% | -17.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.74 | -2906.46 | -1.38 | -1.09 | -2.57 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -2.07 | -1.70 | -1.84 | 14.24 | 3.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.20 | -4.07 | -2.38 | -1.27 | -5.71 |
| Price-to-Operating Cash Flow Ratio | -7.20 | -4.07 | -2.38 | -1.27 | -5.71 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.04 | 0.05 | 0.07 | 0.09 |
| Enterprise Value Multiple | -5.38 | -4.01 | -1.61 | -0.86 | -4.35 |
| Enterprise Value | 10.46M | 6.16M | 3.62M | 2.19M | 5.43M |
| EV to EBITDA | -5.38 | -4.01 | -1.61 | -0.86 | -4.35 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -9.09 | -5.22 | -2.71 | -1.00 | -3.96 |
| EV to Operating Cash Flow | -9.09 | -5.22 | -2.71 | -1.00 | -3.96 |
| Tangible Book Value Per Share | -0.08 | -0.07 | -0.04 | 0.01 | 0.07 |
| Shareholders’ Equity Per Share | -0.08 | -0.07 | -0.04 | 0.01 | 0.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | -0.63 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.05 | -0.00 | -0.06 | -0.08 | -0.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.14 | 1.35 | 1.02 | 1.00 | 2.43 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.52 | 0.71 | 0.58 | 0.86 | 0.45 |
Currency in CAD